Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
American Pharma SummitAmerican Pharma Summit
Not Confirmed
Not Confirmed
18-19 November, 2024
Pharma Manufacturing 2...Pharma Manufacturing 2024
Not Confirmed
Not Confirmed
18-19 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
American Pharma SummitAmerican Pharma Summit
Industry Trade Show
Not Confirmed
18-19 November, 2024
Pharma Manufacturing 2...Pharma Manufacturing 2024
Industry Trade Show
Not Confirmed
18-19 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/medical-breakthroughs-in-2024-alzheimer-s-schizophrenia-copd-mash-see-pathbreaking-treatments
20 Nov 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/11/20/2783148/16626/en/Zevra-Therapeutics-Completes-Acquisition-of-Acer-Therapeutics-in-its-Journey-to-Become-a-Leading-Rare-Disease-Company.html
02 Nov 2023
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2023/11/02/2772310/0/en/Leading-Independent-Proxy-Advisory-Firms-ISS-and-Glass-Lewis-Recommend-Acer-Therapeutics-Shareholders-Vote-FOR-the-Proposed-Merger-and-Related-Proposals.html
30 Aug 2023
// ACCESSWIRE
30 Aug 2023
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2023/08/30/2734780/0/en/Acer-Therapeutics-Reacquires-Worldwide-Development-Commercialization-and-Economic-Rights-to-OLPRUVA-from-Relief-Therapeutics-Excluding-the-Geographical-Europe.html
14 Aug 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/08/14/2725006/0/en/Acer-Therapeutics-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html
26 Jun 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/06/26/2694449/0/en/Acer-Therapeutics-Receives-1-Million-Capital-Infusion-from-Chief-Executive-Officer-and-Founder.html
Details:
Through the acquisition, Zevra will expand its rare disease portfolio and adding commercial product including the recent U.S. commercial approval Olpruva (sodium phenylbutyrate) for the treatment of urea cycle disorders.
Lead Product(s): Sodium Phenylbutyrate
Therapeutic Area: Genetic Disease Brand Name: Olpruva
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Zevra Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 20, 2023
Lead Product(s) : Sodium Phenylbutyrate
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Zevra Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Through the acquisition, Zevra will expand its rare disease portfolio and adding commercial product including the recent U.S. commercial approval Olpruva (sodium phenylbutyrate) for the treatment of urea cycle disorders.
Brand Name : Olpruva
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 20, 2023
Details:
Through the acquisition, Zevra will expand its rare disease portfolio and adding commercial product including the recent U.S. commercial approval Olpruva (sodium phenylbutyrate) for the treatment of UCDs.
Lead Product(s): Sodium Phenylbutyrate
Therapeutic Area: Genetic Disease Brand Name: Olpruva
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Zevra Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 31, 2023
Lead Product(s) : Sodium Phenylbutyrate
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Zevra Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Through the acquisition, Zevra will expand its rare disease portfolio and adding commercial product including the recent U.S. commercial approval Olpruva (sodium phenylbutyrate) for the treatment of UCDs.
Brand Name : Olpruva
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 31, 2023
Details:
Under the terms of the new agreement, Acer will reacquire worldwide development, commercialization and economic rights to OLPRUVA™ (sodium phenylbutyrate) from Relief Therapeutics, excluding the European Union. OLPRUVA™ is approved in the U.S. for treatment of UCDs.
Lead Product(s): Sodium Phenylbutyrate
Therapeutic Area: Genetic Disease Brand Name: Olpruva
Study Phase: ApprovedProduct Type: Small molecule
Recipient: Relief Therapeutics
Deal Size: $56.5 million Upfront Cash: $11.5 million
Deal Type: Licensing Agreement August 30, 2023
Lead Product(s) : Sodium Phenylbutyrate
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Recipient : Relief Therapeutics
Deal Size : $56.5 million
Deal Type : Licensing Agreement
Details : Under the terms of the new agreement, Acer will reacquire worldwide development, commercialization and economic rights to OLPRUVA™ (sodium phenylbutyrate) from Relief Therapeutics, excluding the European Union. OLPRUVA™ is approved in the U.S. for tr...
Brand Name : Olpruva
Molecule Type : Small molecule
Upfront Cash : $11.5 million
August 30, 2023
Details:
The financing will be used for the launch of company's Olpruva (sodium phenylbutyrate), an oral suspension, for the treatment of various disorders, including Maple Syrup Urine Disease (MSUD).
Lead Product(s): Sodium Phenylbutyrate
Therapeutic Area: Genetic Disease Brand Name: Olpruva
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Christopher Schelling
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Financing June 26, 2023
Lead Product(s) : Sodium Phenylbutyrate
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Christopher Schelling
Deal Size : $1.0 million
Deal Type : Financing
Acer Therapeutics Receives $1 Million Capital Infusion from Chief Executive Officer and Founder
Details : The financing will be used for the launch of company's Olpruva (sodium phenylbutyrate), an oral suspension, for the treatment of various disorders, including Maple Syrup Urine Disease (MSUD).
Brand Name : Olpruva
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 26, 2023
Details:
Olpruva (sodium phenylbutyrate) active metabolite is phenylacetate which conjugates with glutamine to form phenylacetylglutamine. Phenylacetylglutamine is excreted by the kidneys, hence providing an alternate vehicle for waste nitrogen excretion.
Lead Product(s): Sodium Phenylbutyrate
Therapeutic Area: Genetic Disease Brand Name: Olpruva
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Relief Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
Lead Product(s) : Sodium Phenylbutyrate
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Relief Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Acer Therapeutics Announces Olpruva™ Commercial Launch Progressing Ahead of Schedule
Details : Olpruva (sodium phenylbutyrate) active metabolite is phenylacetate which conjugates with glutamine to form phenylacetylglutamine. Phenylacetylglutamine is excreted by the kidneys, hence providing an alternate vehicle for waste nitrogen excretion.
Brand Name : Olpruva
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 01, 2023
Details:
ACER-801 (osanetant) is an investigational, novel, non-hormonal, neurokinin 3 receptor (NK3R) antagonist currently being evaluated as a potential treatment option for men with adenocarcinoma of the prostate.
Lead Product(s): Osanetant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: ACER-801
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2023
Lead Product(s) : Osanetant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Acer Therapeutics Announces Topline Results from ACER-801 (Osanetant) Phase 2a Trial
Details : ACER-801 (osanetant) is an investigational, novel, non-hormonal, neurokinin 3 receptor (NK3R) antagonist currently being evaluated as a potential treatment option for men with adenocarcinoma of the prostate.
Brand Name : ACER-801
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 17, 2023
Details:
Olpruva (sodium phenylbutyrate)active metabolite is phenylacetate which conjugates with glutamine to form phenylacetylglutamine. Phenylacetylglutamine is excreted by the kidneys, hence providing an alternate vehicle for waste nitrogen excretion.
Lead Product(s): Sodium Phenylbutyrate
Therapeutic Area: Genetic Disease Brand Name: Olpruva
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Relief Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2023
Lead Product(s) : Sodium Phenylbutyrate
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Relief Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA
Details : Olpruva (sodium phenylbutyrate)active metabolite is phenylacetate which conjugates with glutamine to form phenylacetylglutamine. Phenylacetylglutamine is excreted by the kidneys, hence providing an alternate vehicle for waste nitrogen excretion.
Brand Name : Olpruva
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 15, 2023
Details:
ACER-801 (osanetant) is an investigational, novel, non-hormonal, neurokinin 3 receptor (NK3R) antagonist currently being evaluated as a potential treatment option for men with adenocarcinoma of the prostate.
Lead Product(s): Osanetant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: ACER-801
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Lead Product(s) : Osanetant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ACER-801 (osanetant) is an investigational, novel, non-hormonal, neurokinin 3 receptor (NK3R) antagonist currently being evaluated as a potential treatment option for men with adenocarcinoma of the prostate.
Brand Name : ACER-801
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 13, 2023
Details:
ACER-801 (osanetant) is an investigational, novel, non-hormonal, neurokinin 3 receptor (NK3R) antagonist currently being evaluated as a potential treatment option for men with adenocarcinoma of the prostate.
Lead Product(s): Osanetant
Therapeutic Area: Oncology Brand Name: ACER-801
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details : ACER-801 (osanetant) is an investigational, novel, non-hormonal, neurokinin 3 receptor (NK3R) antagonist currently being evaluated as a potential treatment option for men with adenocarcinoma of the prostate.
Brand Name : ACER-801
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 05, 2023
Details:
OLPRUVA™ (sodium phenylbutyrate), is an oral suspension prescription medicine used for the treatment of rare, genetic disorders like Urea cycle disorders (UCDs) .
Lead Product(s): Sodium Phenylbutyrate
Therapeutic Area: Genetic Disease Brand Name: Olpruva
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Relief Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2022
Lead Product(s) : Sodium Phenylbutyrate
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Relief Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OLPRUVA™ (sodium phenylbutyrate), is an oral suspension prescription medicine used for the treatment of rare, genetic disorders like Urea cycle disorders (UCDs) .
Brand Name : Olpruva
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 27, 2022
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?